Production of materials having an anisotropic structure

    公开(公告)号:US10576694B2

    公开(公告)日:2020-03-03

    申请号:US15498286

    申请日:2017-04-26

    摘要: The present invention relates to a monolithic multi-layered material having at least a first layer, from which anisotropic pores originate, and a second layer, in which the anisotropic pores continue. The present invention further relates to a monolithic medical material having at least a first layer, from which anisotropic pores originate, and a second layer, in which the anisotropic pores continue. The present invention further relates to a process for the production of a multi-layered material having anisotropic pores. It further relates to a multi-layered material which can be produced by the process according to the invention.

    PRODUCTION OF MATERIALS HAVING AN ANISOTROPIC STRUCTURE

    公开(公告)号:US20170224459A1

    公开(公告)日:2017-08-10

    申请号:US15498286

    申请日:2017-04-26

    摘要: The present invention relates to a monolithic multi-layered material having at least a first layer, from which anisotropic pores originate, and a second layer, in which the anisotropic pores continue. The present invention further relates to a monolithic medical material having at least a first layer, from which anisotropic pores originate, and a second layer, in which the anisotropic pores continue. The present invention further relates to a process for the production of a multi-layered material having anisotropic pores. It further relates to a multi-layered material which can be produced by the process according to the invention.

    COMPOUND CONTAINING DEXPANTHENOL
    8.
    发明申请

    公开(公告)号:US20190031699A1

    公开(公告)日:2019-01-31

    申请号:US16148107

    申请日:2018-10-01

    IPC分类号: C07H15/04 A61K8/67 A61Q19/00

    摘要: A compound contains a chemical dexpanthenol bound to a saccharide. A corresponding compound for use in therapeutic and/or cosmetic methods is also provided. The compound may be a skincare compound or a compound configured to be used in prophylaxis of skin diseases and/or treatment of skin diseases or a compound configured to be used as a medicament for accelerating wound healing.

    PROTEOLYSIS TARGETING CHIMERA (PROTAC) FOR DEGRADATION OF AURORA A-KINASE

    公开(公告)号:US20230118911A1

    公开(公告)日:2023-04-20

    申请号:US17906184

    申请日:2021-03-10

    IPC分类号: A61K47/55 A61K47/54 A61P35/00

    摘要: The invention concerns a Proteolysis Targeting Chimera (PROTAC) or a pharmaceutically acceptable salt thereof for degradation of Aurora A-kinase in cells of a mammal which PROTAC has the chemical structure AAB-L-E3B, wherein AAB is a binding unit for Aurora A-kinase, L is a linker and E3B is a binding unit for E3-ubiquitin ligase Cereblon, wherein E3B comprises the structure of thalidomide or of one of its analogs lenalidomide, pomalidomide, and apremilast, wherein L comprises or consists of an alkyl ether residue or a polyalkyl ether residue or an alkyl ether residue or a polyalkyl ether residue in which at least one C—C bond is replaced by a C═C double bond, which polyalkyl ether residue has at least two ether groups or at least two ether groups in which one O-atom is replaced by an S-atom or a part of the O-atoms is replaced by S-atoms or wherein L comprises or consists of an alkyl thioether residue or a polyalkyl thioether residue or an alkyl thioether residue or a polyalkyl thioether residue in which at least one C—C bond is replaced by a C═C double bond, which polyalkyl thioether residue has at least two thioether groups, wherein L connects AAB and E3B via a chain of atoms having five to thirteen subsequently arranged atoms, wherein atoms of functional groups connecting the linker with AAB and E3B are not considered as part of said chain.